DRUG
Midodrine Oral Tablet
midodrine group will receive midodrine 10 mg PO q 8 hr with gradual weaning of IV nor-adrenaline after receiving 4 doses of oral midodrine .
the Effect of Oral Vasopressors for Liberation From IV Vasopressors in Spinal Shock
Status
Unknown
Phase
Phase 2
Enrollment
90
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
the study is developed to evaluate the effect of use of oral vasopressors (midodrine versus minirin) on weaning ICU patients from IV vasopressors (noradrenaline) and compare between them for efficacy in shortage the duration of IV vasopressor and has low complications and side effects.
Interventions
Treatment arms and agents.
DRUG
Minirin oral tablet
Minirin group will receive minirin 60 µg PO q 8 hr with gradual weaning of IV nor-adrenaline after receiving 4 doses of oral minirin .
DRUG
Nor-Adrenaline
control group will receive IV nor-adrenaline and is gradually weaning from it according to routine hospital care without adding oral midodrine or oral minirin .
Timeline
From registration to results.
First posted
Oct 14, 2020
Study start
Oct 15, 2020
Primary completion
Jan 1, 2021
Study completion
Jan 28, 2021
Results posted
Not reported
Registry updated
Oct 14, 2020
Outcomes
What the study measures.
Primary outcomes
liberation the patient from IV vasopressors with maintaining hemodynamics.
Time frame · 48 hrs
Blood pressure will be assessed regularly every 15 minutes
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 60 Years
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Age of 18 - 60 years. * Patients of both genders. * Patients diagnosed by spinal shock and they are in the recovery stage . Exclusion Criteria: * Patient refusal. * Anuric or oliguric patients or patients with chronic kidney disease. * Patients with allergy to medication included in the study.
Study locations
1 registered sites.
Egypt. Showing up to 24 locations stored in the fast local snapshot.
Ahmed Talaat Ahmed
Asyut, Egypt
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Desmopressin.
NCT IDStudyPhase / statusEnrollmentUpdated
Randomized Controlled Clinical Study on the Prophylactic Intraoperative Use of Desmopressin in Complex Sellar Region Tumors
Zhaoyun Zhang · Craniopharyngiomas · Pituitary Macroadenoma
Phase 4
Enrolling by invitation
152
2026-07
Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Cushing Syndrome
Phase 2
Recruiting
140
2026-07
Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial
Hamilton Health Sciences Corporation · Chronic Kidney Diseases · Acute Kidney Injury
Phase 3
Recruiting
100
2026-05
International Multi-center Retrospective Study of Patients With Serum Sodium ≤110 mmol/L to Determine the Relationship Between Osmotic Demyelination Syndrome (ODS) and Rapid Correction of Hyponatremia
Rochester General Hospital · Hyponatremia Symptomatic · Osmotic Demyelination Syndrome
Not applicable
Enrolling by invitation
800
2026-05
DDAVP for Pituitary Adenoma
National Institute of Neurological Disorders and Stroke (NINDS) · Cushing's Disease · Pituitary Adenoma
Not applicable
Recruiting
22
2026-04
Vitamin D Versus Desmopressin Versus Combination Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis and Vitamin D Deficiency
Ain Shams University · Nocturnal Enuresis · Vitamin D Deficiency
Not applicable
Completed
90
2026-03
Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis
Menoufia University · Nocturnal Enuresis in Children · Desmopressin
Not applicable
Completed
398
2026-01
NOCDURNA PASS Study Using Registries in Denmark, Germany and Sweden
Ferring Pharmaceuticals · Adverse Drug Event
Not applicable
Completed
1,099,551
2025-12
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.